“Pluristem reported fiscal 1Q19 (FYE June) with operating expenses of $8.5M and ending the period with $22.5M in cash, excluding an additional ~$7.5M available from grants.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 6.4% and a 41.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $3.50 average price target.
The company has a one-year high of $1.65 and a one-year low of $1.06. Currently, Pluristem has an average volume of 222.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.